Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Guangzhou Baiyunshan Pharmaceutical Holdings Company ( (HK:0874) ) has provided an update.
Guangzhou Baiyunshan Pharmaceutical Holdings Company has approved the participation of its subsidiary GP Fund II in establishing two new investment vehicles, GP Guangkai Fund and GP Liwan Fund, alongside related parties including GP Capital, Guangkai Fund, Angel Master Fund and Liwan Industrial Investment Fund. Under the approved arrangements, GP Fund II will contribute RMB97.5 million to GP Guangkai Fund and RMB99.5 million to GP Liwan Fund, both structured as limited partnerships with GP Capital acting as general partner and manager in certain roles, and with GP Guangkai Fund targeting a total fund size of RMB300 million and initial fundraising of RMB200 million. As GP Capital is controlled by the company’s controlling shareholder GPHL, the transactions are classified as connected transactions under Hong Kong Listing Rules, triggering reporting and announcement obligations but exempting them from independent shareholders’ approval, and the company has cautioned investors that the partnership agreements, although board-approved, have not yet been formally signed. These fund participations reinforce Baiyunshan’s use of venture-style capital structures to support sector-related investments while operating within the regulatory constraints on connected transactions, with limited immediate governance implications given the relatively small size of the deals in listing-rules terms.
The most recent analyst rating on (HK:0874) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Guangzhou Baiyunshan Pharmaceutical Holdings Company stock, see the HK:0874 Stock Forecast page.
More about Guangzhou Baiyunshan Pharmaceutical Holdings Company
Guangzhou Baiyunshan Pharmaceutical Holdings Company is a Chinese healthcare group engaged in the pharmaceutical industry, with operations spanning drug research, manufacturing and related healthcare investment activities. Listed in Hong Kong via H shares, the company uses investment vehicles such as GP Fund II to deploy capital into venture and industrial funds that support the broader medical and health ecosystem.
YTD Price Performance: 7.51%
Average Trading Volume: 1,211,494
Technical Sentiment Signal: Buy
Current Market Cap: HK$44.07B
For a thorough assessment of 0874 stock, go to TipRanks’ Stock Analysis page.